Qingyuan Zhang

机构：Jiangxi University of Traditional Chinese Medicine, Harbin Medical University, Guangxi Medical University, Wuhan University, Third Affiliated Hospital of Harbin Medical University, Zhongnan Hospital of Wuhan University · ORCID：0000-0002-1763-9412

发表论文 115 篇 · 总被引 4601 次 · h-index 31

代表论文

• Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (2024 · New England Journal of Medicine · 被引 433)
• Imlunestrant with or without Abemaciclib in Advanced Breast Cancer (2024 · New England Journal of Medicine · 被引 175)
• Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study (2024 · 癌症：英文版 · 被引 48)
• ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). (2024 · Journal of Clinical Oncology · 被引 13)
• Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial (2025 · Nature Communications · 被引 10)
• Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy (2024 · BMC Cancer · 被引 10)